Christopher Brooks

7.1k total citations · 4 hit papers
85 papers, 5.3k citations indexed

About

Christopher Brooks is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Christopher Brooks has authored 85 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 34 papers in Immunology and 28 papers in Hematology. Recurrent topics in Christopher Brooks's work include CAR-T cell therapy research (28 papers), Toxin Mechanisms and Immunotoxins (19 papers) and Cancer-related Molecular Pathways (18 papers). Christopher Brooks is often cited by papers focused on CAR-T cell therapy research (28 papers), Toxin Mechanisms and Immunotoxins (19 papers) and Cancer-related Molecular Pathways (18 papers). Christopher Brooks collaborates with scholars based in United States, Canada and France. Christopher Brooks's co-authors include Wei Gu, Muyang Li, Wei Gu, Ning Kon, Jianyuan Luo, Delin Chen, Richard Baer, Foon Wu-Baer, M Li and Naveen Pemmaraju and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Biological Chemistry.

In The Last Decade

Christopher Brooks

83 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p53 Ubiquitination: Mdm2 and Beyond

2006 713 citations Christopher Brooks, Wei Gu Molecular Cell profile →
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2

2003 622 citations Muyang Li, Christopher Brooks et al. profile →
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation

2003 620 citations Christopher Brooks, Wei Gu Current Opinion in Cell Biology profile →
A Dynamic Role of HAUSP in the p53-Mdm2 Pathway

2004 527 citations Muyang Li, Christopher Brooks et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Brooks United States	26	3.6k	2.9k	671	654	598	85	5.3k
Giovanna Chiorino Italy	37	3.0k 0.8×	1.3k 0.5×	1.3k 1.9×	289 0.4×	578 1.0×	113	4.8k
Warren Fiskus United States	48	5.1k 1.4×	1.2k 0.4×	468 0.7×	399 0.6×	511 0.9×	141	6.3k
Mohamed Rahmani United States	47	3.9k 1.1×	1.4k 0.5×	554 0.8×	717 1.1×	586 1.0×	95	5.7k
Lori S. Friedman United States	42	4.8k 1.3×	2.5k 0.9×	1.1k 1.6×	414 0.6×	530 0.9×	106	7.4k
Antje Menssen Germany	20	2.3k 0.6×	814 0.3×	1.3k 1.9×	203 0.3×	538 0.9×	31	3.3k
Sheau-Yann Shieh Taiwan	28	6.2k 1.7×	4.6k 1.6×	1.3k 1.9×	277 0.4×	314 0.5×	39	7.4k
Lee Ann Remington United States	13	3.5k 1.0×	3.5k 1.2×	981 1.5×	474 0.7×	398 0.7×	15	5.8k
Brian Gabrielli Australia	47	4.6k 1.3×	2.1k 0.7×	887 1.3×	270 0.4×	412 0.7×	129	6.0k
Anthony N. Karnezis United States	41	4.2k 1.1×	2.4k 0.8×	1.5k 2.2×	786 1.2×	647 1.1×	90	7.9k
Philip M. Reaper United Kingdom	16	4.2k 1.2×	2.0k 0.7×	721 1.1×	216 0.3×	362 0.6×	19	5.4k

Countries citing papers authored by Christopher Brooks

Since Specialization

Citations

This map shows the geographic impact of Christopher Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Brooks more than expected).

Fields of papers citing papers by Christopher Brooks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Brooks. The network helps show where Christopher Brooks may publish in the future.

Co-authorship network of co-authors of Christopher Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Brooks. A scholar is included among the top collaborators of Christopher Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Brooks. Christopher Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roussel, Xavier, Sabeha Biichlé, Maxime Fredon, et al.. (2025). New leads to enhance tagraxofusp efficacy in pDC-AML. PubMed. 2(2). 100066–100066.

Patnaik, Mrinal M., Tariq I. Mughal, Christopher Brooks, Ross Lindsay, & Naveen Pemmaraju. (2021). Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leukemia & lymphoma. 62(11). 2568–2586. 14 indexed citations

Lane, Andrew A., Anthony S. Stein, Jacqueline S. Garcia, et al.. (2021). Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. Blood. 138(Supplement 1). 2346–2346. 27 indexed citations

Barve, Minal, E. Gabriela Chiorean, Patricia LoRusso, et al.. (2020). 564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours. Annals of Oncology. 31. S485–S486. 3 indexed citations

Togami, Katsuhiro, Jason Stephansky, Mahmoud Ghandi, et al.. (2019). DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. Journal of Clinical Investigation. 129(11). 5005–5019. 57 indexed citations

Mani, Rajeswaran, Bhavani Gopalakrishnan, Xiaokui Mo, et al.. (2018). The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34⁺CD123⁺ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 103(8). 1288–1297. 33 indexed citations

Brooks, Christopher, Peter R. McDonald, Jonathan D. Schwartz, et al.. (2015). SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity. Blood. 126(23). 4433–4433. 1 indexed citations

Brooks, Christopher & Wei Gu. (2011). The impact of acetylation and deacetylation on the p53 pathway. Protein & Cell. 2(6). 456–462. 231 indexed citations

Brooks, Christopher & Wei Gu. (2011). p53 regulation by ubiquitin. FEBS Letters. 585(18). 2803–2809. 157 indexed citations

10.

Brooks, Christopher & Wei Gu. (2010). New insights into p53 activation. Cell Research. 20(6). 614–621. 86 indexed citations

11.

Kon, Ning, Y. Kobayashi, M Li, et al.. (2009). Inactivation of HAUSP in vivo modulates p53 function. Oncogene. 29(9). 1270–1279. 149 indexed citations

12.

Brooks, Christopher & Wei Gu. (2009). Anti-aging protein SIRT1: A role in cervical cancer?. Aging. 1(3). 278–280. 7 indexed citations

13.

Brooks, Christopher & Wei Gu. (2008). How does SIRT1 affect metabolism, senescence and cancer?. Nature reviews. Cancer. 9(2). 123–128. 359 indexed citations

14.

Chen, Dong, Scott Reierstad, Zhihong Lin, et al.. (2007). Prostaglandin E2 Induces Breast Cancer–Related Aromatase Promoters via Activation of p38 and c-Jun NH2-Terminal Kinase in Adipose Fibroblasts. Cancer Research. 67(18). 8914–8922. 64 indexed citations

15.

Brooks, Christopher, Muyang Li, & Wei Gu. (2007). Mechanistic Studies of MDM2-mediated Ubiquitination in p53 Regulation. Journal of Biological Chemistry. 282(31). 22804–22815. 35 indexed citations

16.

Brooks, Christopher, M Li, Min Hu, Yigong Shi, & Wei Gu. (2007). The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene. 26(51). 7262–7266. 119 indexed citations

17.

Brooks, Christopher & Wei Gu. (2006). p53 Ubiquitination: Mdm2 and Beyond. Molecular Cell. 21(3). 307–315. 713 indexed citations breakdown →

18.

Gu, Wei, Jianyuan Luo, Christopher Brooks, Anatoly Nikolaev, & Muyang Li. (2004). Dynamics of the p53 Acetylation Pathway. Novartis Foundation symposium. 259. 197–207. 43 indexed citations

19.

Li, Muyang, Christopher Brooks, Ning Kon, & Wei Gu. (2004). A Dynamic Role of HAUSP in the p53-Mdm2 Pathway. Molecular Cell. 13(6). 879–886. 527 indexed citations breakdown →

20.

Brooks, Christopher & Wei Gu. (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Current Opinion in Cell Biology. 15(2). 164–171. 620 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact